PL2121610T3 - Nowy półprodukt oraz sposób przydatny w wytwarzaniu {2-[1-(3,5-bistrifluorometylo-benzylo)-5-pirydyn-4-ylo-1H-[1,2,3]triazol-4-ilo]-pirydyn-3-ylo}-(2-chlorofenylo)-metanonu - Google Patents
Nowy półprodukt oraz sposób przydatny w wytwarzaniu {2-[1-(3,5-bistrifluorometylo-benzylo)-5-pirydyn-4-ylo-1H-[1,2,3]triazol-4-ilo]-pirydyn-3-ylo}-(2-chlorofenylo)-metanonuInfo
- Publication number
- PL2121610T3 PL2121610T3 PL07865137T PL07865137T PL2121610T3 PL 2121610 T3 PL2121610 T3 PL 2121610T3 PL 07865137 T PL07865137 T PL 07865137T PL 07865137 T PL07865137 T PL 07865137T PL 2121610 T3 PL2121610 T3 PL 2121610T3
- Authority
- PL
- Poland
- Prior art keywords
- pyridin
- methanone
- triazol
- chlorophenyl
- trifluoromethyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/44—Radicals substituted by doubly-bound oxygen, sulfur, or nitrogen atoms, or by two such atoms singly-bound to the same carbon atom
- C07D213/46—Oxygen atoms
- C07D213/50—Ketonic radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/44—Radicals substituted by doubly-bound oxygen, sulfur, or nitrogen atoms, or by two such atoms singly-bound to the same carbon atom
- C07D213/53—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Pulmonology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Dermatology (AREA)
- Pyridine Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US87085106P | 2006-12-20 | 2006-12-20 | |
| EP07865137.9A EP2121610B1 (en) | 2006-12-20 | 2007-12-04 | Novel intermediate and process useful in the preparation of {2-[1-(3,5-bis-trifluoromethyl-benzyl)-5-pyridin-4-yl-1h-[1,2,3]triazol-4-yl]-pyridin-3-yl}-(2-chlorophenyl)-methanone |
| PCT/US2007/086319 WO2008079600A1 (en) | 2006-12-20 | 2007-12-04 | Novel intermediate and process useful in the preparation of {2-[1-(3,5-bis-trifluoromethyl-benzyl)-5-pyridin-4-yl-1h-[1,2,3]triazol-4-yl]-pyridin-3-yl}-(2-chlorophenyl)-methanone |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL2121610T3 true PL2121610T3 (pl) | 2014-09-30 |
Family
ID=39273082
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL07865137T PL2121610T3 (pl) | 2006-12-20 | 2007-12-04 | Nowy półprodukt oraz sposób przydatny w wytwarzaniu {2-[1-(3,5-bistrifluorometylo-benzylo)-5-pirydyn-4-ylo-1H-[1,2,3]triazol-4-ilo]-pirydyn-3-ylo}-(2-chlorofenylo)-metanonu |
Country Status (22)
| Country | Link |
|---|---|
| US (4) | US8772496B2 (pl) |
| EP (1) | EP2121610B1 (pl) |
| JP (1) | JP5443168B2 (pl) |
| KR (1) | KR20090081028A (pl) |
| CN (1) | CN101568523A (pl) |
| AU (1) | AU2007337255A1 (pl) |
| BR (1) | BRPI0721069A2 (pl) |
| CA (1) | CA2671770C (pl) |
| DK (1) | DK2121610T3 (pl) |
| EA (1) | EA200970604A1 (pl) |
| EC (1) | ECSP099441A (pl) |
| ES (1) | ES2471990T3 (pl) |
| HR (1) | HRP20140613T1 (pl) |
| IL (1) | IL198775B (pl) |
| MX (1) | MX2009006636A (pl) |
| NO (1) | NO20092370L (pl) |
| PL (1) | PL2121610T3 (pl) |
| PT (1) | PT2121610E (pl) |
| RS (1) | RS53386B (pl) |
| SI (1) | SI2121610T1 (pl) |
| WO (1) | WO2008079600A1 (pl) |
| ZA (1) | ZA200903578B (pl) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2009006636A (es) * | 2006-12-20 | 2009-06-30 | Lilly Co Eli | Nuevos intermediarios y procesos utiles en la rpeparacion de {2-[1-(3,5-bis-trifluorometil-bencil)-5-piridin-4-il-1h-[1,2,3]tr iazol-4-il]-piridin-3-il}-(2-clorofenil)-metanona. |
| US10098859B2 (en) | 2012-09-05 | 2018-10-16 | Amri Ssci, Llc | Cocrystals of p-coumaric acid |
| AU2016226006B2 (en) | 2015-03-04 | 2021-03-04 | Vanda Pharmaceuticals Inc. | Method of treatment with tradipitant |
| US10287287B2 (en) | 2015-08-17 | 2019-05-14 | Eli Lilly And Company | Process development of a pyridine-containing NK-1 receptor antagonist |
| BR112020004964A2 (pt) | 2017-09-13 | 2020-09-15 | Vanda Pharmaceuticals Inc. | método que consiste em administrar uma quantidade de tradipitant eficaz, aperfeiçoamento, método aperfeiçoado para tratar um paciente que sofre de prurido ou dermatite atópica com tradipitant, e, métodos para tratar um paciente com prurido ou dermatite atópica, para selecionar e para determinar uma dosagem de tradipitant eficaz, para determinar que um paciente tem probabilidade de responder ao tratamento de dermatite atópica com tradipitant e para identificar um paciente. |
| EP3710000A1 (en) * | 2017-11-17 | 2020-09-23 | Vanda Pharmaceuticals Inc. | Method of treatment of gastrointestinal diseases with tradipitant |
| US10821099B2 (en) | 2018-09-28 | 2020-11-03 | Vanda Pharmaceuticals Inc. | Use of tradipitant in motion sickness |
| EP3890735A1 (en) | 2018-12-03 | 2021-10-13 | Vanda Pharmaceuticals Inc. | Method of treatment with tradipitant |
| JP2023520369A (ja) * | 2020-03-26 | 2023-05-17 | バンダ・ファーマシューティカルズ・インコーポレイテッド | トラジピタントによる下気道感染症の治療 |
| WO2023019084A1 (en) | 2021-08-12 | 2023-02-16 | Vanda Pharmaceuticals Inc. | Treatment of gastric accommodation with tradipitant |
| WO2024138040A1 (en) | 2022-12-21 | 2024-06-27 | Vanda Pharmaceuticals Inc. | Methods of treatment with tradipitant |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20040600A1 (es) | 2002-04-26 | 2004-09-15 | Lilly Co Eli | Derivados de triazol como antagonistas del receptor de taquicinina |
| US7381826B2 (en) * | 2003-10-24 | 2008-06-03 | Eli Lilly And Company | Crystalline forms of {2-[1-(3,5-bis-trifluoromethyl-benzyl)-5-pyridin-4-yl-1H-[1,2,3]triazol-4-yl]-pyridin-3-yl}-(2-chlorophenyl)-methanone |
| WO2006083711A1 (en) * | 2005-02-01 | 2006-08-10 | Eli Lilly And Company | Tachykinin receptor antagonists |
| MX2009006636A (es) * | 2006-12-20 | 2009-06-30 | Lilly Co Eli | Nuevos intermediarios y procesos utiles en la rpeparacion de {2-[1-(3,5-bis-trifluorometil-bencil)-5-piridin-4-il-1h-[1,2,3]tr iazol-4-il]-piridin-3-il}-(2-clorofenil)-metanona. |
-
2007
- 2007-12-04 MX MX2009006636A patent/MX2009006636A/es active IP Right Grant
- 2007-12-04 RS RS20140349A patent/RS53386B/en unknown
- 2007-12-04 AU AU2007337255A patent/AU2007337255A1/en not_active Abandoned
- 2007-12-04 JP JP2009543027A patent/JP5443168B2/ja active Active
- 2007-12-04 CA CA2671770A patent/CA2671770C/en active Active
- 2007-12-04 BR BRPI0721069-8A patent/BRPI0721069A2/pt not_active Application Discontinuation
- 2007-12-04 ES ES07865137.9T patent/ES2471990T3/es active Active
- 2007-12-04 CN CNA2007800466993A patent/CN101568523A/zh active Pending
- 2007-12-04 EA EA200970604A patent/EA200970604A1/ru unknown
- 2007-12-04 PL PL07865137T patent/PL2121610T3/pl unknown
- 2007-12-04 DK DK07865137.9T patent/DK2121610T3/da active
- 2007-12-04 PT PT78651379T patent/PT2121610E/pt unknown
- 2007-12-04 EP EP07865137.9A patent/EP2121610B1/en active Active
- 2007-12-04 KR KR1020097012894A patent/KR20090081028A/ko not_active Application Discontinuation
- 2007-12-04 US US12/515,794 patent/US8772496B2/en active Active
- 2007-12-04 WO PCT/US2007/086319 patent/WO2008079600A1/en active Application Filing
- 2007-12-04 SI SI200731483T patent/SI2121610T1/sl unknown
-
2009
- 2009-05-14 IL IL198775A patent/IL198775B/en active IP Right Grant
- 2009-05-22 ZA ZA200903578A patent/ZA200903578B/xx unknown
- 2009-06-17 EC EC2009009441A patent/ECSP099441A/es unknown
- 2009-06-22 NO NO20092370A patent/NO20092370L/no not_active Application Discontinuation
-
2014
- 2014-03-27 US US14/227,857 patent/US20140206877A1/en not_active Abandoned
- 2014-06-27 HR HRP20140613TT patent/HRP20140613T1/hr unknown
-
2015
- 2015-11-10 US US14/937,051 patent/US9708291B2/en active Active
-
2017
- 2017-06-15 US US15/623,550 patent/US10035787B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| MX2009006636A (es) | 2009-06-30 |
| NO20092370L (no) | 2009-09-16 |
| US20160060250A1 (en) | 2016-03-03 |
| AU2007337255A1 (en) | 2008-07-03 |
| US9708291B2 (en) | 2017-07-18 |
| IL198775B (en) | 2018-08-30 |
| BRPI0721069A2 (pt) | 2014-02-04 |
| KR20090081028A (ko) | 2009-07-27 |
| RS53386B (en) | 2014-10-31 |
| US8772496B2 (en) | 2014-07-08 |
| US20100056795A1 (en) | 2010-03-04 |
| EP2121610A1 (en) | 2009-11-25 |
| CN101568523A (zh) | 2009-10-28 |
| HRP20140613T1 (hr) | 2014-08-15 |
| JP5443168B2 (ja) | 2014-03-19 |
| WO2008079600A1 (en) | 2008-07-03 |
| SI2121610T1 (sl) | 2014-08-29 |
| US10035787B2 (en) | 2018-07-31 |
| US20140206877A1 (en) | 2014-07-24 |
| PT2121610E (pt) | 2014-06-25 |
| ES2471990T3 (es) | 2014-06-27 |
| US20170283394A1 (en) | 2017-10-05 |
| CA2671770A1 (en) | 2008-07-03 |
| EP2121610B1 (en) | 2014-04-02 |
| ECSP099441A (es) | 2009-07-31 |
| IL198775A0 (en) | 2010-02-17 |
| JP2010513546A (ja) | 2010-04-30 |
| EA200970604A1 (ru) | 2009-10-30 |
| CA2671770C (en) | 2015-09-15 |
| DK2121610T3 (da) | 2014-06-30 |
| ZA200903578B (en) | 2010-07-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL198775A0 (en) | Novel intermediate and process useful in the preparation of {2-[1-(3,5-bis-trifluoromethyl-benzyl)-5-pyridin-4-yl-1h-[1,2,3]triazol-4-yl]-pyridin-3-yl}-(2-chlorophenyl)-methanone | |
| IL200990A (en) | 4'-o-isoindulin derivatives are converted, their vehicles and methods of use | |
| IL192241A0 (en) | Improved process for the preparation of 4-(benzimidazolylmethylamino)-benzamides and the salts thereof | |
| ZA200903367B (en) | 4-Phenyl-6-(2,2,2-trifluoro-1-phenylethoxy) pyrimidine-based compounds and methods of their use | |
| IL202293A0 (en) | 1,(,3)5-substituted imidazoles, their use in the treatment of hypertension and methods for their preparation | |
| IL179589A0 (en) | Injection port and method of making the same | |
| AP2006003830A0 (en) | Piperidine derivatives and their use as insecticides, acaricides, molluscicides or nematicides | |
| IL184499A0 (en) | Pyrazole derivatives for the inhibition of cdk's and gsk's | |
| GB2417592B (en) | Authenticity verification of articles | |
| GB2412239B (en) | Ferroelectric capacitor hydrogen barriers and methods for fabricating the same | |
| EP1932833A4 (en) | NITROGENATED HETEROCYCLIC COMPOUND AND PHARMACEUTICAL COMPOSITION CONTAINING THEREOF | |
| IL181674A0 (en) | Processes for the preparation of substituted 2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolines | |
| IL185034A0 (en) | 1,5-diarylpyrrole derivatives, preparation method thereof and application of same in therapeutics | |
| EP1717231A4 (en) | SUBSTITUTED AZOLEO COMPOUND AND CORRESPONDING PREPARATION AND APPLICATION | |
| HK1101811A1 (en) | Article, filter media and method of making the filter media | |
| IL188861A0 (en) | 1,4-dihydropyridine-fused heterocycles, process for preparing the same, use and compositions containing them | |
| PL378587A1 (pl) | Sposób wytwarzania (S)-(-)-2-amino-6-n-propyloamino-4,5,6,7-tetrahydrobenzotiazolu i/lub jego soli | |
| ZA200506090B (en) | Architecture, programming model and API's | |
| EP2067747A4 (en) | POROUS TITANIUM OXIDE AND PROCESS FOR PRODUCTION THEREOF | |
| ZA200705614B (en) | Pyrazole derivatives for the inhibition of CDK's and GSK's | |
| PL1890695T3 (pl) | Zastosowanie 2,5-dipodstawionych pochodnych tiazol-4-onu w lekach | |
| EP1734005A4 (en) | TANTALIUM OXIDE AND / OR NIOBIUM OXIDE AND PROCESS FOR THE PREPARATION THEREOF | |
| AP2261A (en) | Process and methods for the preparation of optically active CIS-2-hydroxymethyl-4-(cytosin-1'-YL)-1,3-oxathiolane or pharmaceutically acceptable saltsthereof. | |
| PL376122A1 (pl) | Sposób wytwarzania rekombinowanej szczepionki przeciwko krwotocznej chorobie królików, szczepionka oraz zastosowanie antygenu rekombinowanego białka do wytwarzania szczepionki | |
| SI1922320T1 (sl) | Derivati 5-piridazinil-1-azabiciklo(3.2.1)oktana, njihova priprava in njihova terapevtska uporaba |